Phesgo 1200/600mg Vial Of 15ml Solution For Injection
Medical Description
Phesgo solution for injection is an anti-cancer medication containing a combination of pertuzumab and trastuzumab used by cancer specialists to treat specific types of breast cancer. It targets a protein called HER2, which is overexpressed in certain breast cancers. By binding to HER2, Phesgo solution for injection inhibits the growth of these cancer cells.
Phesgo solution for injection is used in various treatment settings, including early-stage breast cancer with high HER2 levels and metastatic breast cancer. It may be administered alone or in combination with other cancer treatments like chemotherapy or hormone therapy, depending on the specific type and stage of the cancer.
Product Summary
Offer Price | ₹470800.00 |
You Save | ₹64200.00 (12% on MRP) |
Contains | Trastuzumab(40.0 Mg/Ml) + Pertuzumab(80.0 Mg/Ml) |
Uses | Breast cancers |
Side effects | Diarrhea, nausea, vomiting, stomatitis (inflammation of the mouth), constipation, and dyspepsia |
Therapy | ANTI-NEOPLASTIC-VARDHMAN |
Uses of PHESGO 1200/600MG VIAL OF 15ML SOLUTION FOR INJECTION
Contraindications of PHESGO 1200/600MG VIAL OF 15ML SOLUTION FOR INJECTION
- If you are allergic to trastuzumab or any of the other ingredients of Phesgo solution for injection
- If you have severe breathing problems at rest due to your cancer or if you need oxygen treatment.
Side effects of PHESGO 1200/600MG VIAL OF 15ML SOLUTION FOR INJECTION
- Diarrhea
- Nausea
- Vomiting
- Stomatitis
- Constipation
- Dyspepsia
- Abdominal pain
- Fatigue
- Neutropenia
- Anemia
- Febrile neutropenia
- Leukopenia
Precautions and Warnings of PHESGO 1200/600MG VIAL OF 15ML SOLUTION FOR INJECTION
Pregnancy
Breast Feeding
Driving
Alcohol
Other General Warnings
- You have ever had or have a hepatitis infection.
- You have a history of cardiac conditions, such as heart failure, coronary artery disease, or arrhythmias.
- You have previously received anthracycline-based chemotherapy.
- You experience symptoms of cardiac dysfunction, including shortness of breath, fatigue, or swelling.
- You have poorly controlled hypertension or other cardiovascular risk factors.
- You have a history of myocardial infarction, angina requiring treatment, or clinically significant valvular disease.
- You suffer from asthma or other respiratory conditions.
- You develop symptoms during or after infusion, such as shortness of breath, wheezing, hypotension, hypertension, urticaria, or chest pain.
- You experience delayed infusion-related symptoms hours or days after treatment.
- You have dyspnea (difficulty breathing) at rest due to advanced malignancy or other comorbidities.
- You experience any new or worsening respiratory symptoms, such as cough, chest tightness, or difficulty breathing.
- You are pregnant, planning a pregnancy, or breastfeeding.
- You experience severe side effects, including persistent nausea, fatigue, or signs of infection.
- You notice worsening symptoms or develop new symptoms during treatment.
- You are taking other medications, especially those known to affect the heart or lungs, such as taxanes, gemcitabine, or radiation therapy.
Directions for Use of PHESGO 1200/600MG VIAL OF 15ML SOLUTION FOR INJECTION
Storage and disposal of PHESGO 1200/600MG VIAL OF 15ML SOLUTION FOR INJECTION
- Store in a refrigerator (2 °C – 8 °C). Keep the container in the outer carton to protect it from light.
- Keep it out of the reach of children.
Dosage of PHESGO 1200/600MG VIAL OF 15ML SOLUTION FOR INJECTION
Overdose
Missed a Dose
Mode of Action of PHESGO 1200/600MG VIAL OF 15ML SOLUTION FOR INJECTION
How Does It Work?
Interactions of PHESGO 1200/600MG VIAL OF 15ML SOLUTION FOR INJECTION
Interactions with other medicines
Content Details
Ravindra Ghongade
B. Pharm
Dr. Nikita Toshi
BDS (Bachelor of Dental Surgery)
References
- Herceptin 150mg Powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc) [Internet]. Medicines.org.uk. 2025 [cited 6 January 2025]
- Herceptin 150mg Powder for concentrate for solution for infusion - Patient Information Leaflet (PIL) - (emc) [Internet]. Medicines.org.uk. 2025 [cited 6 January 2025]
- Phesgo 600 mg/600 mg solution for injection - Summary of Product Characteristics (SmPC) - (emc) [Internet]. Medicines.org.uk. 2025 [cited 6 January 2025]
Other Products from this Brand
Health Articles
Top-Tests we cover:
Top-Selling Healthcare Products:
Top-Selling Medicines:
Top-Searched Medicines: